| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18596272 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 102 journal articles in the PubMed database | Email to a friend | | |
| Sherman SI, Wirth LJ, Droz JP, et al.
Motesanib diphosphate in progressive differentiated thyroid cancer. [Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't]
N Engl J Med 2008 Jul 3; 359(1):31-42.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Pennell NA, Daniels GH, Haddad RI, et al.
A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. [JOURNAL ARTICLE]
Thyroid 2007 Nov 6.
Abstract | Full Citation | Find Related Articles | | Tuttle RM, Fleisher M, Francis GL, et al.
Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. [Journal Article]
J Clin Endocrinol Metab 2002 Apr; 87(4):1737-42.
Abstract | Full Citation | Find Related Articles | | Motzer RJ, Michaelson MD, Redman BG, et al.
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. [Clinical Trial, Phase II, Journal Article, Multicenter Study]
J Clin Oncol 2006 Jan 1; 24(1):16-24.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Rosen LS, Kurzrock R, Mulay M, et al.
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. [Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
J Clin Oncol 2007 Jun 10; 25(17):2369-76.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Motzer RJ, Hutson TE, Tomczak P, et al.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. [Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
N Engl J Med 2007 Jan 11; 356(2):115-24.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Burstein HJ, Elias AD, Rugo HS, et al.
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. [Journal Article]
J Clin Oncol 2008 Apr 10; 26(11):1810-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Kohlfuerst S, Igerc I, Gallowitsch HJ, et al.
Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases? [Journal Article]
Thyroid 2006 Nov; 16(11):1113-9.
Abstract | Full Citation | | Rixe O, Bukowski RM, Michaelson MD, et al.
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. [JOURNAL ARTICLE]
Lancet Oncol 2007 Oct 22.
Abstract | Full Citation |   |
|
| |
Advertise on this site.
|
